We assessed the broadly used, off-label combination of sofosbuvir, daclatasvir, simeprevir, and ribavirin in direct-acting antiviral-experienced patients, as recommended in current guidelines despite scarce data. After 24 weeks' treatment, sustained virological response 12 weeks after the end of treatment was achieved in 6 patients (60%). Two cirrhotic patients relapsed and 2 discontinued treatment due to serious adverse events.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1093/cid/cix214 | DOI Listing |
Publication Analysis
Top Keywords
ribavirin direct-acting
8
direct-acting antiviral-experienced
8
antiviral-experienced patients
8
sofosbuvir-daclatasvir-simeprevir ribavirin
4
patients
4
patients hepatitis
4
hepatitis assessed
4
assessed broadly
4
broadly off-label
4
off-label combination
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!